Compare ISD & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISD | FLGT |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.8M | 511.2M |
| IPO Year | N/A | 2016 |
| Metric | ISD | FLGT |
|---|---|---|
| Price | $13.06 | $20.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 117.1K | ★ 362.4K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 9.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | N/A | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.53 | $13.46 |
| 52 Week High | $14.79 | $31.04 |
| Indicator | ISD | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 70.80 |
| Support Level | $12.57 | $13.91 |
| Resistance Level | $13.17 | $23.70 |
| Average True Range (ATR) | 0.16 | 0.60 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 94.25 | 97.01 |
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.